Dr. Levin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1250 S Collegeville Rd
Collegeville, PA 19426Phone+1 610-917-5731- Is this information wrong?
Education & Training
- Rush University Medical CenterFellowship, Hematology and Medical Oncology, 1990 - 1992
- Rush University Medical CenterResidency, Internal Medicine, 1987 - 1990
- University of Illinois College of MedicineClass of 1987
Certifications & Licensure
- PA State Medical License 2002 - 2024
Publications & Presentations
PubMed
- 55 citationsPhase III Trial of Casopitant, a Novel Neurokinin-1 Receptor Antagonist, for the Prevention of Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemothe...Jørn Herrstedt, Wichit Apornwirat, Ahmed Shaharyar, Zeba Aziz, Fausto Roila, Simon Van Belle, Mark W. Russo, Jeremey Levin, Salabha Ranganathan, Mary E. Guckert, Steve...> ;Journal of Clinical Oncology. 2009 Nov 10
- 1 citationsA phase I trial of weekly paclitaxel plus prolonged oral eniluracil/5-fluorouracil in patients with refractory malignancies.Suzanne F. Jones, F. Anthony Greco, John D. Hainsworth, Jeffrey Patton, John H. Barton, Noel T. Willcutt, Margaret N. Baker, Paul V. McGuirt, Jeremey Levin, Howard A. ...> ;The Oncologist. 2002 Oct 1
- 65 citationsRandomized, Open-Label, Phase III Study of a 28-Day Oral Regimen of Eniluracil Plus Fluorouracil Versus Intravenous Fluorouracil Plus Leucovorin as First-Line Therapy ...Richard L. Schilsky, Jeremey Levin, William H. West, A. Wong, Bruce Colwell, M. Thirlwell, Rafat Ansari, William N. Bell, Robin L. White, Barbara Yates, Paul V. McGuir...> ;Journal of Clinical Oncology. 2002 Mar 15
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: